Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
Author(s): Vijay Chopra, Javed Butler, Dinesh Khullar ,et al Start date: Nov 17, 2025
Breakthrough Mineralocorticoid Receptor Antagonists in Cardiovascular Care brings together renowned cardiovascular experts Dr Vijay Chopra, Dr Javed Butler, Dr Dinesh Khullar, and Prof John McMurray to address critical challenges in heart failure management and hypertension treatment. This comprehensive session explores innovative approaches to mineralocorticoid receptor antagonist (MRA) therapy,… View more

Heart Failure

Prevention & Chronic Conditions
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
Author(s): Javed Butler , Dinesh Khullar , John JV McMurray , et al Added: 2 months ago
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He… View more

Heart Failure

Prevention & Chronic Conditions
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s): Rishi Sethi , Pravesh Vishwakarma , Akshyaya Pradhan Added: 1 year ago

Heart Failure

MI/ACS
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 6 months ago

Cardiovascular Renal Metabolic
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 6 months ago

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 3 months ago

Heart Failure
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 3 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 8 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Cardiovascular Renal Metabolic

Heart Failure